Beta-2-glycoprotein I dependent lupus anticoagulants form stable bivalent antibody Beta-2-glycoprotein I complexes on phospholipid surfaces

Thrombosis and Haemostasis

Volumn 79, Issue 1, 1998, Pages 79-86

  Arnout, J ^a   Wittevrongel, C ^a   Vanrusselt, M ^a   Hoylaerts, M ^a   Vermylen, J ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BETA2 GLYCOPROTEIN 1; EPITOPE; IMMUNOGLOBULIN F(AB) FRAGMENT; LUPUS ANTICOAGULANT; MONOCLONAL ANTIBODY; PHOSPHATIDYLETHANOLAMINE; PHOSPHOLIPID;

ANTICOAGULATION; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; BLOOD CLOTTING; COMPLEX FORMATION; CONTROLLED STUDY; HUMAN; PRIORITY JOURNAL; SENSOR;

EID: 0031984075     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1614224     Document Type: Article

References (46)

1. McNeil HP, Chesterman CN, Krilis SA. Immunology and clinical importance of antiphospholipid antibodies. Adv Immunol 1991; 49: 193-280.
2. Vermylen J, Blockmans D, Spitz B, Arnout J, Grillet B. Thrombosis as an immune phenomenon. Baillière's Clinical Immunology and Allergy 1987; 1: 619-41.
3. Love PE, Santoro SA. Antiphospholipid antibodies: Anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Ann Intern Med 1990; 112: 682-98.
4. Hughes GRV, Harris EN, Gharavi AE. The anticardiolipin syndrome. J Rheumatol 1986; 13: 486-9.
5. Exner T, Triplett DA, Taberner D, Machin SJ. Guidelines for testing and revised criteria for lupus anticoagulants. Thromb Haemost 1991; 65: 320-2.
6. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. Thromb Haemost 1995; 74: 1185-90.
7. Harris EN, Gharavi AE, Boey ML, Patel BM, Mackworth-Young CG, Loizou S, Hughes GRV. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983; ii: 1211-4.
8. Loizou S, McCrea JD, Rudge AC, Reynolds R, Boyle CC, Harris EN. Measurement of anticardiolipin antibodies by an enzyme-linked immunosorbent assay (ELISA): standardization and quantitation of results. Clin Exp Immunol 1985; 62: 738-45.
9. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta-2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87: 4120-4.
10. Galli M, Comfurius P, Maassen C, Hemker HC, de Baets MH, van Breda-Vriesman PJC, Barbui T, Zwaal RFA, Bevers EM. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335: 1544-7.
11. Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 1990; 336: 177-8.
12. Vermylen J, Arnout J. Is the antiphospholipid syndrome caused by antibodies directed against physiologically relevant phospholipid-protein complexes? J Lab Clin Med 1992; 120: 10-2.
13. Hunt JE, McNeil HP, Morgan GJ, Crameri RM, Krilis SA. A phospholipid-beta 2-glycoprotein I complex is an antigen for anticardiolipin antibodies occurring in autoimmune disease but not with infection. Lupus 1992; 1: 75-81.
14. Wagenknecht DR, McIntyre JA. Changes in beta 2-glycoprotein I antigenicity induced by phospholipid binding. Thromb Haemost 1993; 69: 361-5.
15. 2-Glycoprotein I reactivity of monoclonal anticardiolipin antibodies from patients with the antiphospholipid syndrome. Arthritis Rheum 1994; 37: 1453-61.
16. Pengo V, Biasiolo A, Fior MG. Autoimmune antiphospholipid antibodies are directed against a cryptic epitope expressed when β2-glycoprotein I is bound to a suitable surface. Thromb Haemost 1995; 73: 29-34.
17. Arvieux J, Roussel B, Jacob MC, Colomb MG. Measurement of antiphospholipid antibodies by ELISA using beta 2-glycoprotein I as an antigen. J Immunol Methods 1991; 143: 223-9.
18. Matsuura E, Igarashi Y, Yasuda T, Triplett DA, Koike T. Anticardiolipin antibodies recognize β2-Glycoprotein I structure altered by interaction with an oxygen modified solid phase surface. J Exp Med 1994; 179: 457-62.
19. Viard JP, Amoura Z, Bach JF. Association of anti-beta 2-glycoprotein I antibodies with lupus-type circulating anticoagulant and thrombosis in systemic lupus erythematosus. Am J Med 1992; 93: 181-6.
20. Martinuzzo ME, Forastiero RR, Carreras LO. Anti beta 2 glycoprotein I antibodies: detection and association with thrombosis. Br J Haematol 1995; 89, 397-402.
21. Roubey RAS, Eisenberg RA, Harper MF, Winfield JB. Anticardiolipin autoantibodies recognize β2-glycoprotein I in the absence of phospholipid. Importance of Ag density and bivalent binding. J Immunol 1995; 154: 954-60.
22. Oosting JD, Derksen RH, Entjes HT, Bouma BN, de Groot PG. Lupus anticoagulant activity is frequently dependent on the presence of beta 2-glycoprotein I. Thromb Haemost 1992; 67: 499-502.
23. Roubey RA, Pratt CW, Buyon JP, Winfield JB. Lupus anticoagulant activity of autoimmune antiphospholipid antibodies is dependent upon beta 2-glycoprotein I. J Clin Invest 1992; 90: 1100-4.
24. Galli M, Comfurius P, Barbui T, Zwaal RF, Bevers EM. Anticoagulant activity of beta 2-glycoprotein I is potentiated by a distinct subgroup of anticardiolipin antibodies. Thromb Haemost 1992; 68: 297-300.
25. Bevers EM, Galli M, Barbui T, Comfurius P, Zwaal RF. Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost 1991; 66: 629-32.
26. Wurm H. B-2-glycoprotein I (apolipoprotein H) interactions with phospholipid vesicles. Int J Biochem 1984; 16: 511-5.
27. Arnout J, Spitz B, Wittevrongel C, Vanrusselt M, Van Assche A, Vermylen J. High-dose intravenous immunoglobulin treatment of a pregnant patient with an antiphospholipid antibody syndrome: immunological changes associated with a succesful outcome. Thromb Haemost 1994; 71: 741-7.
28. Galfré G, Milstein C. Preparation of monoclonal antibodies: strategies and procedures. Methods Enzymol 1981; 73: 3-46.
29. Fazekas de St. Groth S, Scheidegger D. Production of monoclonal antibodies: strategy and tactics. J Immunol Methods 1980; 35: 1-21.
30. Anderson PM, Potter M. Induction of plasma cell tumors in Balb/c mice with 2,6.10.14 etramethyl-pentadecane (pristane) Nature 1969; 222: 994-5.
31. Ey PL, Prowse SJ, Jenkin CR. Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using protein A-sepharose. Immunochemistry 1978; 15: 429-36.
32. Arnout J, Vanrusselt M, Huybrechts E, Vermylen J. Optimisation of the dilute prothrombin time for the detection of the lupus anticoagulant by use of a recombinant tissue thromboplastin. Br J Haematol 1994; 87: 94-9.
33. Rauch J, Tannenbaum M, Janoff AS. Distinguishing plasma lupus anticoagulants from anti-factor antibodies using hexagonal (II) phase phospholipids. Thromb Haemost 1989; 62: 892-6.
34. Jönsson U, Malmqvist M. Real time biospecific interaction analysis: the integration of surface plasmon resonance detection, general biospecific interface chemistry and microfluidities into one analytical system. Adv Biosensors 1992; 2: 291-336.
35. Nakane PA, Kawaoi A. Peroxidase labeled antibody. A new method for conjugation. J Histochem Cytochem 1974; 22: 1084-91.
36. Karlsson R, Michaelsson A, Mattsson L. Kinetic analysis of monoclonal antibody-antigen interactions with a new biosensor based analytical system. J Immunol Methods 1991; 145: 229-40.
37. BIAtechnology note 106. Uppsala, Sweden: Pharmacia Biosensor AB; 1995.
38. Kertesz Z, Yu B, Steinkasserer A, Haupt H, Benham A, Sim R. Characterization of binding of human B2-glycoprotein I to cardiolipin. Biochem J 1995; 310: 315-21.
39. 2-glycoprotein T complexes to lipid membranes. Biochemistry 1996; 35: 13833-42.
40. 2GP I binding to phospholipids. J Clin Invest 1997; 99: 2260-8.
41. Romans DG, Tilley CA, Dorrington KJ. Monogamous bivalency of IgG antibodies. I. Deficiency of branched ABHI-active oligosaccharide chains on red cells of infants causes the weak antiglobulin reactions in hemolytic disease of the newborn due to ABO incompatibility. J Immunol 1980; 124: 2807.
42. Arnout J. The pathogenesis of the antiphospholipid syndrome: a hypothesis based on parallelisms with heparin-induced thrombocytopenia. Thromb Haemost 1996; 75: 536-41.
43. Arvieux J, Roussel B, Pouzol P, Colomb MG. Platelet activating properties of murine monoclonal antibodies to beta 2-glycoprotein I. Thromb Haemost 1993; 70: 336-41.
44. 2 glycoprotein I monoclonal antibodies via Fcg receptor II. J Leukoc Biol 1995; 57: 387-94.
45. Horbach DA, van Oort E, Donders RCJM, Derksen RHWM, de Groot PG. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies. Thromb Haemost 1996; 76; 916-24.
46. Simantov R, LaSala JM, Lo SK, Gharavi AE, Sammaritano LR, Salmon JE. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest 1995; 96: 2211-9.